News

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Texas Biomed taps new research leadership to help craft aggressive game plan

Joanne Turner has joined Texas Biomedical Research Institute as its new vice president of research. COURTESY ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Biotech firm completes study on skin wart treatment
February 20, 2014

By Mike W. Thomas, San Antonio Business Journal

Local biotech firm ViroXis Corp. is wrapping up a Phase 2 clinical study of its treatment for a virus that causes skin warts.

The final patient of the 183-person enrolled study has completed treatment and the results will be known once the data has been analyzed. ViroXis has developed a drug for treating the Human Papilloma Virus (HPV) using oils from the East Indian Sandalwood tree. The study is being funded by the proceeds of a $5 million Series B private offering.

ViroXis also announced plans to initiate a second Phase 2 clinical study in a new direction to test its effect on Molluscum contagiosum (MCV) in a pediatric population. MCV is a highly contagious pox virus skin infection for which there are currently no approved prescription treatments.

"ViroXis has quickly emerged as leader in the development of botanical drug products, a new and important group of drug candidates afforded a distinct approval process by the (Food and Drug Administration)," says Ian Clements, CEO of ViroXis.

 

Stay informed. Subscribe to BioMed SA news alerts.